ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
NRTI/NRTI/NNRTI single-tablet regimen

Lamivudine with tenofovir disoproxil and doravirine

Brand names: Delstrigo

Adult dose

Dose: 1 tab (300mg lamivudine / 245mg tenofovir DF / 100mg doravirine) PO OD
Route: PO
Frequency: OD

Clinical pearls

  • Once-daily complete HIV-1 regimen in treatment-naive adults
  • Monitor renal function and bone health (TDF)

Contraindications

  • Concurrent strong CYP3A4 inducers (rifampicin, enzalutamide, phenytoin, carbamazepine, St John's wort)

Side effects

  • Headache
  • Nausea
  • Renal impairment (TDF)
  • Reduced bone density (TDF)
  • Hepatotoxicity

Interactions

  • Strong CYP3A4 modulators
  • Metformin (raised by INSTI but doravirine here)
  • Rifampicin

Monitoring

  • Viral load
  • U&E
  • LFTs
  • Bone density
  • Phosphate

Reference: BNF; BHIVA; SmPC; https://bnf.nice.org.uk/drugs/lamivudine-with-tenofovir-disoproxil-and-doravirine/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways